Bibliography
- Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006;46(4):20
- Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006;22(6):8
- Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 2007;33:7
- Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 2008;24(4):7
- Yanni JM, Graff G, Hellberg MR. Topically administered composition containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders. Alcon Laboratories, Inc., assignee. US5475034;1995
- Miyake K, Ogawa T, Tajika T, et al. Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. J Ocul Pharmacol Ther 2008;24(6):6
- Bucci FA Jr, Waterbury LD. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg 2008;34(9):1509
- Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007;114:10
- Ohara K, Ohkuba A, Miyamoto T, et al. Effect of bromfenac sodium on postoperative inflammation. Jpn J Cataract Refract Surg 2004;18:12
- Miyanaga M, Miyai T, Nejima R, et al. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol 2009;87(3):6
- Asano S, Miyake K, Ota I, et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg 2008;34(1):7
- Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg 2007;33:4
- Wittpenn JR, Silverstein S, Heier J, et al. Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 2008;146(7):554
- Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 2005;89:3
- Kim A, Stark W. Are topical NSAIDs needed for routine cataract surgery? Am J Ophthalmol 2008;146(4):3
- Rho DS, Tractenberg R, Soll SM, Markovitz BJ. Treatment of acute pseudophakic cystoid macular edema: bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5%. Proceedings of the 112th Annual American Academy of Ophthalmology (AAO) Meeting, Atlanta, GA, November 11, 2008. PA077.
- Hashimoto T, Igarashi A, Hoshina F, et al. Effects of nonsteroidal anti-inflammatory drugs on experimental allergic conjunctivitis in Guinea pigs. J Ocul Pharmacol Ther 2003;19(6):9
- Miyake-Kashima M, Takano Y, Tanaka M, et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol 2004;48:4
- Olson NY, LC, Godfrey WA. Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child 1988;142(12):4
- Galor A, TJ. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am 2007;33(4):10
- Imrie FR, DA. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol 2007;18(3):8
- Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Opthalmologica 2003;217:10
- Olthoff CM, SJ, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112(6):9
- ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%. 2008 12/8/08; Available from: http://www.news-medical.net/news/2008/12/08/ 43859.aspx [Cited 6/3/09]
- Reviglio VE, RT, Li QJ, et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea. J Cataract Refract Surg 2003;29(5):9
- Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf 2002;25(4):233-50
- Mian SI, Gupta A, Pineda R 2nd. Corneal ulceration and perforation with ketorolac tromethamine (Acular) use after PRK. Cornea 2006;25(2):232-4
- Isawi H, DD. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg 2007;33:3
- Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea 2006;25(2):224-7
- Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006;15(4):213-20
- Hunter EB, Johnston PE, Tanner G, et al. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 1999;94(8):2299-301
- Moses PL, Schroeder B, Alkhatib O, et al. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999;94(5):1393-6
- Stewart RH, GL, Shiffman ML, et al. Bromfenac Ophthalmic Solution 0.09% Study Group. The systemic safety of bromfenac ophthalmic solution 0.09%. J Ocul Pharmacol Ther 2007;23(6):9
- Kashiwagi K, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost. Br J Ophthalmol 2003;87(3):297-301
- Sher NA, Golben MP, Bond W, et al. Comparison of topical Xibrom (bromfenac ophthalmic solution 0.09%) vs Acular LS (ketorolac ophthalmic solution 0.4%) for the control of pain, photophobia, and discomfort following photorefractive keratectomy (PRK). J Refract Surg 2009;25:214-20
- Chynn EW, Wang XJ, Givergis R, Younesi P. Evaluation of the analgesic efficacy and safety of bromfenac sodium 0.09% ophthalmic solution and ketorolac tromethamine following LASEK, LASIK, AND Epi-LASIK surgery. American Society of Cataract & Refractive Surgery (ARCRS) Meeting, San Diego, CA, April 27-May 2, 2007
- Grant CA. Combination therapy: Lucentis (ranibizumab injection) and Xibrom (bromfenac ophthalmic solution) 0.09% in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration. 80th Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Ft. Lauderdale, FL, April 27-May 1, 2008. 563/A531